Citadel Advisors’s AstraZeneca AZNH Stock Holding History

Citadel Advisors’s Portfolio AZNH Stock Details AZNH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,096	Closed	-$602K	–	14553
2025 Q4	$602K	Sell	11,096 -75,911	-87%	-$4.02M	﹤0.01%	8587
2025 Q3	$4.02M	Buy	87,007 +36,096	+71%	+$1.64M	﹤0.01%	4755
2025 Q2	$2.09M	Sell	50,911 -28,411	-36%	-$1.2M	﹤0.01%	5631
2025 Q1	$3.63M	Buy	79,322 +42,682	+116%	+$1.96M	﹤0.01%	4428
2024 Q4	$1.54M	Buy	+36,640	New	+$1.67M	﹤0.01%	6170

Citadel Advisors's AZNH Position: Q1 2026 in Review

Citadel Advisors sold out of AstraZeneca (AZNH) in Q1 2026, closing a stake of 11,096 shares — an estimated $602K sold.

Citadel Advisors first reported a position in AZNH in Q4 2024 and held it in 5 quarters. The position peaked at $4.02M in Q3 2025. 0 funds tracked by Wall St. Rank hold AZNH as of Q1 2026.

Citadel Advisors reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 11,096 AstraZeneca shares in Q1 2026, an estimated $602K.
Citadel Advisors first reported a position in AstraZeneca in Q4 2024 and held it in 5 quarters.
Citadel Advisors's AstraZeneca position peaked at $4.02M in Q3 2025.
0 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.